The present disclosure provides compositions, methods of preparing, and method of use of a composition comprising: (a) about 0.05 wt % to about 10.0 wt % ethylenediaminetetraacetic acid, a salt thereof, a chelating agent, or a combination thereof; (b) from about 2.0 wt % to 50.0 wt % ethanol (ET), isopropyl alcohol (IPA), or a combination thereof; and (c) from about 0.015 μg/mL to about 100.0 μg/mL chlorhexidine, a salt thereof, or a combination thereof. These compositions, as disclosed herein, eliminate greater the 95% of planktonic or biofilm cells from a central venous access device.

An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a substrate having a hemostatic agent and an active pharmaceutical ingredient selectively positioned on the substrate. Kits, systems and methods are disclosed.

A liquid embolic composition of natural polymers, water, and angiographic contrast agents improves neurovascular interventions, making them more reliable, safe, and affordable. The embolic material is made of a single component activated by blood calcium ion, which triggers coagulation, and that offers superior mechanical stability and does not cause fragmentation in the target vessel. The material retains superior long-term mechanical durability after deployment and provides sufficient visualization under fluoroscopy with iodine-based angiographic contrast compounds or other radiopaque compositions. Described herein are aqueous solutions that enable a high concentration gellan gum (greater than 0.5 wt %) to retain sol state even at the range of body temperature (30-40° C.). This discovery means that it is possible to increase the concentration of gellan gum without losing its inject-ability, yet significantly improve its mechanical stability after delivery.

Disclosed are a fibrinogen solution and a thrombin solution. The fibrinogen solution comprises fibrinogen at a concentration of at least 40 mg/ml, factor XIII, pharmaceutically acceptable additives and water. The dynamic viscosity of the fibrinogen solution measured at 20° C. increases at most by 35% after storing the solution at 20° C. for 30 days. The thrombin solution comprises thrombin, pharmaceutically acceptable additives and water. The thrombin activity decreases at most by 15% after storing the solution at 25° C. for 14 days. Also disclosed is a fibrin sealant kit with a first container comprising the fibrinogen solution and a second container comprising the thrombin solution. Further, methods for preparing a fibrin sealant and methods for treating a wound are disclosed.

The present invention relates to a wound covering with prominent biocompatible and accelerated wound-healing and its preparation method thereof. The wound covering comprises a film prepared from collagen and Dopa-containing protein—mussel adhesive protein, which is immobilized on collagen by chemical cross-linking, thus enhances the stability of protein structure and maintains the activity of collagen and mussel adhesive protein. The wound covering has excellent mechanical strength and can be trimmed into any shape; it accelerates tissue epithelisation and promotes wound healing with good biocompatibility, non-adhesive to the wound and no further wound damages.

It is provided a composition comprising phytic acid or a pharmaceutically acceptable salt thereof, for use in reducing or preventing microorganisms' proliferation and/or encrustations caused by a urinary tract device implanted in a subject, thereby preventing or treating clinical complications related to microorganisms' proliferation and/or encrustations. The composition can further comprise a urine acidifier such as methionine, a crystallization inhibitor such as theobromine and/or other agents.

Pharmaceutical compositions, more specifically poloxamer copolymer-based compositions and hyaluronic acid-based compositions, containing amelogenin, are useful for promoting periodontal or orthopedic soft or hard tissue regeneration, wound closure, and skin regeneration and rejuvenation. The composition can contain a non-biodegradable thermosensitive pharmaceutically acceptable poloxamer copolymer in an amount of 18% to 30% by weight; amelogenin in an amount of 0.005% to 3% by weight; a disaccharide in an amount of 0.05% to 5% by weight; and an amino acid selected from alanine, glycine, isoleucine, leucine, proline, valine, and a mixture thereof in an amount of 0.05% to 5% by weight.

The present invention concerns a polyelectrolyte coating comprising at least one polycationic layer consisting of at least one polycation consisting of n repetitive units having the formula (1) and at least one polyanionic layer consisting of hyaluronic acid. The polyelectrolyte coating has a biocidal activity and the invention thus further refers to the use of said polyelectrolyte coating for producing a device, in particular a bacteriostatic medical device, more particularly an implantable device, comprising said polyelectrolyte coating, and a method for preparing said device and a kit.

An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a substrate and a hemostatic agent. The substrate includes a first piece and a second piece that is joined with the first piece. The first piece includes the hemostatic agent and the second piece includes an active pharmaceutical ingredient. Kits, systems and methods are disclosed.

The present invention relates to novel formulations comprising a sprayable composition comprising tranexamic acid and chitosan for use in the treatment of wounds or injuries, in particular for use as a topical hemostatic composition or for surgical intervention and the process for preparation thereof.